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OBJECTIVES We studied the contribution of putative risk genotypes at the angiotensin I–converting
enzyme inhibitor (ACE D/D) and plasminogen activator inhibitor-1 (PAI-1 4G/4G) loci to
all-cause and cardiovascular mortality in a population-based cohort.
BACKGROUND The ACE D/D and PAI-1 4G/4G genotypes have been consistently associated with elevated
plasma activities of the gene products. Their role in cardiovascular disease, although explored
intensively, is still equivocal.
METHODS The ACE and PAI-1 genotypes were determined in 648 subjects $85 years old. In a
cross-sectional analysis, the genotype distributions in a subset of 356 elderly subjects who
were born in Leiden, The Netherlands, were compared with those in 250 young subjects
whose families originated from the same geographic region. In addition, the complete cohort
of elderly subjects was followed over 10 years for all-cause and cardiovascular mortality and
was stratified according to genotype.
RESULTS In the cross-sectional analysis, the ACE and PAI-1 genotype distributions were similar in
elderly and young subjects. In the prospective follow-up study, however, the age-adjusted risk
of fatal ischemic heart disease was increased threefold (95% confidence interval [CI] 1.2 to
7.6) in elderly men carrying the PAI-1 4G/4G genotype. The risk of all-cause mortality was
not increased among elderly subjects carrying the PAI-1 4G/4G (relative risk [RR] 0.9, 95%
CI 0.7 to 1.1) or the ACE D/D genotype (RR 0.9, 95% CI 0.7 to 1.1), nor did we observe
elevated risks of death from all cardiovascular diseases combined. There was no interaction
between the genotypes.
CONCLUSIONS The PAI 4G/4G genotype may be a risk factor for fatal ischemic heart disease in elderly men.
The impact of moderately increased ACE and PAI-1 activities associated with the ACE D/D
and PAI-1 4G/4G genotypes is too small to affect mortality in the general population. (J Am
Coll Cardiol 1999;34:1176–83) © 1999 by the American College of Cardiology
Over the last years a number of common gene variants have
been identified that are associated with plasma levels of the
gene products and the risk of cardiovascular disease. Most
studies performed thus far have not addressed the associa-
tion of these variants with fatal cardiovascular disease or
have only included a small number of fatal cases. Also, very
few studies have yet explored how combinations of possible
risk genotypes affect disease risk. Establishing such genetic
risk profiles is only feasible when relatively large populations
are available and the putative risk alleles have a high
frequency in the general population. Two highly frequent
genetic variants that may be linked to cardiovascular disease
risk have been identified in the genes encoding angiotensin
I–converting enzyme (ACE) inhibitor and plasminogen
activator inhibitor-1 (PAI-1).
ACE catalyzes the conversion of angiotensin I to angio-
tensin II, which is a potent vasoconstrictor and promotes
vascular smooth muscle cell growth and degrades bradyki-
nin, which is a vasodilator. The ACE insertion/deletion
(I/D) polymorphism arises from the presence or absence of
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an alu repeat located in intron 16 of the ACE gene
(frequency of ACE D-allele in whites ’0.54) (1). The
ACE D-allele is associated with increased ACE activity in
plasma (1,2) and tissue (3). Several studies have reported an
increased frequency of the ACE D/D genotype in survivors
of myocardial infarction as compared with healthy subjects
(4–7). However, these results have been challenged by the
negative findings from other studies (8–15). In addition to
the ongoing debate on the deleteriousness of the ACE D/D
genotype, a beneficial influence on survival in very old age
was suggested by the increased frequency of the ACE D/D
genotype in French centenarians (16).
The primary inhibitor of fibrinolysis is PAI-1. A 4/5-
guanine-tract (4G/5G) polymorphism was identified in the
promoter of the PAI-1 gene 675 base pairs upstream from
the start of transcription (17). The PAI-1 4G allele is
associated with elevated PAI-1 levels in plasma (frequency
of PAI-1 4G-allele in whites ’0.52) (17–19). This associ-
ation is especially strong among subjects with relatively high
plasma levels of triglycerides, insulin or glucose (20,21).
Studies in vitro indicate that the 4G-allele is unable to bind
a repressor and is associated with increased transcription of
the PAI-1 gene (17,18). In addition, a very low density
lipoprotein responsive element was found to partly overlap
the guanine tract, which may provide a molecular explana-
tion for the modification effect by triglycerides (22). The
elevated plasma PAI-1 level in 4G/4G homozygotes may
result in an increased risk of coronary heart disease as a
consequence of a diminished fibrinolytic capacity. Studies
investigating this hypothesis, however, have produced con-
flicting results (18,19,23–26).
If a deleterious effect of the ACE D-allele and the PAI-1
4G-allele is present, carriers of both risk alleles may be
especially susceptible to disease owing to the link that exists
between the renin–angiotensin system and fibrinolytic func-
tion. Infusion of angiotensin II increases plasma PAI-1
activity in humans (27), and recently, two studies showed
that the ACE D/D genotype was associated with elevated
PAI-1 levels in plasma (28,29). Hence, the ACE and PAI-1
polymorphisms may be involved in cardiovascular disease in
part by the same etiologic pathway.
The aim of the present study was to assess whether the
ACE and PAI-1 polymorphisms, either separately or in
combination, are associated with mortality in the general
population. This was done using two designs within a
population-based study among subjects $85 years old
(Leiden 85-plus study [30]). The influence of the gene
variants on mortality before the age of 85 years was studied
in a cross-sectional design by comparing the genotype
distributions in Leiden-born subjects $85 years old with
those in young subjects whose families originated from the
same geographic region (31). The relation of the gene
variants to all-cause and cardiovascular mortality above the
age of 85 years was investigated in a prospective study with
a 10-year follow-up period using the complete elderly
cohort. During follow up, the all-cause mortality rate was
89% and the cardiovascular mortality rate was 38%.
METHODS
Subjects. The Leiden 85-plus study is a population-based
study in which all inhabitants of Leiden, The Netherlands,
aged $85 years were invited to take part (30). Of a total of
1,258 eligible subjects, 221 died before enrollment, which
lasted from December 1, 1986 to March 1, 1988. Of the
1,037 remaining subjects, 977 (94%) participated and were
medically interviewed at home. Diabetes was diagnosed on
the basis of the previous history or a glucose level .11.0
mmol/liter in a nonfasting blood sample, or the use of
medication for treatment of diabetes. After the exclusion of
subjects with a non-Dutch (n 5 29) or unknown (n 5 69)
place of birth, sufficient cell material was available from 666
(188 men and 478 women) subjects for the present genetic
study. Deoxyribonucleic acid was extracted by protein pre-
cipitation using potassium acetate and chloroform. The
ACE genotypes were determined as previously described
(32). Because the ACE I/D genotype is erroneously
mistyped as ACE D/D in up to 5% of cases, the presence of
the ACE D/D genotype was confirmed with an insertion-
specific polymerase chain reaction (PCR) amplification
(33). The PAI-1 4G/5G genotypes were determined using
an allele-specific PCR amplification described by Falk et al.
(34). It was not possible to determine the ACE genotype in
26 cases and the PAI-1 genotype in 22 cases for technical
reasons. The ACE and PAI genotypes were independently
assessed by two observers. The study was approved by the
Medical Ethics Committee of the Leiden University, and
informed consent was obtained from all participants.
Cross-sectional analysis. The ACE and PAI-1 genotype
distributions were compared between elderly subjects $85
years old and young control subjects. To avoid false associ-
ations with the ACE and PAI-1 polymorphisms due to
differences in geographic origin rather than age, only those
subjects $85 years old who were born in Leiden (n 5 356,
55%) were compared with a control population that con-
sisted of 250 (139 men and 111 women) blood donors 18 to
40 years old of Dutch descent with either two Leiden-born
parents or one Leiden-born parent and the other born
within a 12-km distance from Leiden. Information regard-
ing the birthplace of their grandparents was obtained from
a written questionnaire.
The elderly subjects were survivors of a cohort born in
Abbreviations and Acronyms
ACE 5 angiotensin I–converting enzyme
CI 5 confidence interval
I/D 5 insertion/deletion
PAI-1 5 plasminogen activator inhibitor-1
PCR 5 polymerase chain reaction
RR 5 relative risk
1177JACC Vol. 34, No. 4, 1999 Heijmans et al.
October 1999:1176–83 ACE and PAI-1 Gene Variants and Mortality
Leiden between 1887 and 1901. Therefore, an investigation
was made of whether the young control population was
likely to represent the Leiden genotype distribution of two
generations before. The frequencies of the ACE D/D
genotype were 27.1%, 27.0%, 27.5% and 22.4% among
young subjects with either one or more (n 5 203), two or
more (n 5 178), three or more (n 5 120) and four (n 5 76)
Leiden-born grandparents, respectively. For the PAI-1
4G/4G genotype these frequencies were 29.6%, 30.9%,
30.8% and 27.6%, respectively. Thus, the ACE and PAI-1
genotype frequencies in control subjects were independent
of the number of grandparents born in Leiden, except for
the relatively low frequency of the ACE D/D genotype in
the young subjects with four Leiden-born grandparents.
Among elderly subjects born in Leiden, however, the
prevalence of the ACE D/D genotype was somewhat higher
(29.2%) as compared with elderly subjects born elsewhere in
The Netherlands (28.6%). These data indicate that no
specific Leiden ACE or PAI-1 genotype distribution ex-
isted around the year 1900.
Prospective follow-up study. All participants in the Lei-
den 85-plus study were followed up for mortality until
October 1, 1996. Among 640 subjects genotyped for the
ACE polymorphism and 646 for the PAI-1 polymorphism,
two were lost to follow-up, leaving 638 and 644 subjects,
respectively, for the prospective follow-up study. Primary
causes of death were obtained from the Dutch Central
Bureau of Statistics and categorized according to the 9th
International Classification of Diseases (ICD-9) (35) for
cardiovascular disease (ICD-9 codes 390–459), ischemic
heart disease (codes 410–414) and cerebrovascular disease
(codes 430–438).
Statistical analysis. In the cross-sectional analysis, distri-
butions of alleles and genotypes were compared by using the
chi-square test. Mortality risks up to the age of 85 years
were estimated with the exposure odds ratio. In the pro-
spective follow-up study, survival times for subjects were
computed from the date of the home visit to the date of one
of the following events: death from a specific cause, death
from any cause or October 1, 1996. Survival was estimated
using the Kaplan-Meier product-limit method. Age- and
gender-adjusted (when applicable) mortality risks and 95%
confidence intervals (CIs) were estimated with Cox propor-
tional hazards models. Causes of death were assumed to be
independent. P values ,0.05 were considered to indicate
statistical significance, and all p values were based on
two-sided tests. The analyses were performed using the
SPSS statistical software, version 6.1 (Chicago, Illinois).
RESULTS
ACE I/D polymorphism. The ACE genotype distribution
was 22.5% (I/I), 49.7% (I/D) and 27.8% (D/D) in the
cohort of subjects $85 years old (n 5 640). For the cross-
sectional analysis, ACE genotype frequencies in the elderly
subjects born in Leiden (n 5 353, 55% of the complete
cohort) were compared with those in young subjects 18 to
40 years old whose families originated from the Leiden area
(n 5 250) (Table 1). Genotype frequencies in both groups
were in agreement with the distribution predicted by the
Hardy-Weinberg equilibrium and similar to that in other
white groups (36). The distribution of ACE genotypes was
similar in elderly and young subjects (p 5 0.46) and also not
significantly different for men (p 5 0.81) and women (p 5
0.81) when analyzed separately. On the basis of genotype
frequencies, the mortality risk up to the age of 85 years
associated with the ACE D/D genotype was estimated at
0.8 (95% CI 0.5 to 1.2) as compared with that associated
with the ACE I/I genotype.
Ten-year survival of the complete cohort of elderly
subjects according to ACE genotype is shown in Figure 1.
During follow-up, the all-cause mortality rate was 89% and
the cardiovascular mortality rate was 38%. The all-cause
mortality risk of elderly ACE D/D carriers was 0.9 (95% CI
0.7 to 1.1) as compared with that of ACE I/I carriers (Table
2). The ACE D/D genotype was not associated with the
risk of death due to cardiovascular disease (relative risk [RR]
0.8, 95% CI 0.6 to 1.2) (Table 2). Similar estimates were
obtained for men and women, except for the ACE I/D
genotype. In men, the heterozygous genotype was associ-
ated with an increased mortality risk. This is not compatible
with a recessive or (co-)dominant effect.
PAI-1 4G/5G polymorphism. The PAI-1 genotype fre-
quencies were 19.2% (5G/5G), 52.9% (4G/5G) and 27.9%
(4G/4G) in the cohort of elderly subjects $85 years old
(n 5 646). The PAI-1 genotype distributions in the elderly
subjects born in Leiden (n 5 354) and in young subjects
Table 1. Angiotensin-Converting Enzyme Inhibitor Genotype
Distributions in Subjects $85 Years Old and Young Subjects
Whose Families Originated From the Same Geographic Region
ACE
Genotype
Subjects
Elderly* Young†
All subjects n 5 353 n 5 250
I/I 73 (20.7%) 62 (24.8%)
I/D 177 (50.1%) 122 (48.8%)
D/D 103 (29.2%) 66 (26.4%)
Men only n 5 112 n 5 139
I/I 26 (23.2%) 37 (26.6%)
I/D 57 (50.9%) 69 (49.6%)
D/D 29 (25.9%) 33 (23.7%)
Women only n 5 241 n 5 111
I/I 47 (19.5%) 25 (22.5%)
I/D 120 (49.8%) 53 (47.7%)
D/D 74 (30.7%) 33 (29.7%)
*Median age 89 years (range 85 to 100). †Median age 31 years (range 18 to 40). Data
are presented as number (%) of subjects.
ACE 5 angiotensin-converting enzyme; D/D 5 deletion/deletion; I/D 5
insertion/deletion; I/I 5 insertion/insertion.
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whose families originated from the Leiden area (n 5 250)
were in Hardy-Weinberg equilibrium (Table 3). The geno-
type frequencies in young subjects were similar to those
previously reported for white subjects (23,25). No overall
significant differences were observed in PAI-1 genotype
distribution (p 5 0.37) or for men and women separately
(p 5 0.11 and p 5 0.78, respectively). The mortality risk up
to the age of 85 years associated with the PAI-1 4G/4G
genotype was estimated at 0.8 (95% CI 0.5 to 1.2) as
compared with that associated with the PAI-1 5G/5G
genotype.
Figure 2 shows the 10-year survival of elderly subjects
according to PAI-1 genotype. Elderly carriers of the PAI-1
4G/4G genotype were not at an increased risk for death
from any cause (RR 0.9, 95% CI 0.7 to 1.1) or from
cardiovascular disease (RR 0.9, 95% CI 0.6 to 1.3) as
compared with carriers of the PAI-1 5G/5G genotype
(Table 4). Similar estimates were obtained for men and
women.
Among men, the PAI-1 4G/4G genotype was associated
with an increased risk of fatal ischemic heart disease (Table 4).
Assuming a recessive effect (i.e., combining PAI-1 4G/5G and
5G/5G as a single reference group), the RR was estimated at
3.1 (95% CI 1.2 to 7.6, p 5 0.015). None of the men carrying
the PAI-1 4G/4G genotype who died of ischemic heart
disease were diagnosed as having diabetes at baseline.
Figure 1. Kaplan-Meier estimate of 10-year cumulative survival
according to ACE genotype for subjects $85-years-old.
Table 2. Ten-Year All-Cause and Cardiovascular Disease Mortality Risks According to Angiotensin-Converting Enzyme Inhibitor
Genotype in Subjects $85 Years Old
ACE
Genotype n
All-Cause
Cardiovascular
Disease
Ischemic Heart
Disease
Cerebrovascular
Disease
RR* 95% CI RR 95% CI RR 95% CI RR 95% CI
All subjects 638 n 5 569 n 5 241 n 5 61 n 5 79
I/I 144 1 1 1 1
I/D 316 1.2 (0.9–1.4) 1.3 (0.9–1.8) 1.2 (0.6–2.2) 1.1 (0.6–1.8)
D/D 178 0.9 (0.7–1.1) 0.8 (0.6–1.2) 0.7 (0.3–1.4) 0.8 (0.4–1.5)
Men only 182 n 5 160 n 5 62 n 5 20 n 5 19
I/I 46 1 1 1 1
I/D 85 1.6 (1.1–2.3) 1.7 (0.9–3.3) 1.7 (0.6–4.7) 1.4 (0.4–4.6)
D/D 51 1.2 (0.8–1.9) 1.2 (0.6–2.5) 0.6 (0.1–2.5) 1.8 (0.5–6.1)
Women only 456 n 5 409 n 5 179 n 5 41 n 5 60
I/I 98 1 1 1 1
I/D 231 1.0 (0.8–1.3) 1.1 (0.8–1.7) 1.0 (0.4–2.1) 0.9 (0.5–1.8)
D/D 127 0.8 (0.6–1.0) 0.7 (0.5–1.1) 0.6 (0.3–1.6) 0.6 (0.3–1.2)
*Relative risk (RR) indicates the mortality risk as estimated by a Cox proportional hazard model adjusted for age at baseline.
CI 5 confidence interval; other abbreviations as in Table 1.
Table 3. Plasminogen Activator Inhibitor-1 Genotype
Distributions in Subjects $85 Years Old and Young Subjects
Whose Families Originated From the Same Geographic Region
PAI-1
Genotype
Subjects
Elderly* Young†
All subjects n 5 354 n 5 250
5G/5G 67 (18.9%) 59 (23.6%)
4G/5G 190 (53.7%) 125 (50.0%)
4G/4G 97 (27.4%) 66 (26.4%)
Men only n 5 111 n 5 139
5G/5G 17 (15.3%) 36 (25.9%)
4G/5G 61 (55.0%) 70 (50.4%)
4G/4G 33 (29.7%) 33 (23.7%)
Women only n 5 243 n 5 111
5G/5G 50 (20.6%) 23 (20.7%)
4G/5G 129 (53.1%) 55 (49.5%)
4G/4G 64 (26.3%) 33 (29.7%)
*Median age 89 years (range 85 to 100). †Median age 31 years (range 18 to 40). Data
are presented as the number (%) of subjects.
PAI-1 5 plasminogen activator inhibitor-1.
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The analyses were repeated for elderly subjects with
diabetes (n 5 69) because they can be expected to have
elevated plasma triglycerides, insulin and glucose. In this
subset, the all-cause mortality risks associated with the
PAI-1 4G/4G and 4G/5G genotypes were 0.4 (95% CI 0.2
to 0.9) and 0.6 (95% CI 0.3 to 1.2), respectively, as
compared with that associated with the 5G/5G genotype.
Combined effects of ACE I/D and PAI-1 4G/5G poly-
morphisms. The prevalence of homozygosity for both the
ACE and the PAI-1 risk allele was similar among elderly
subjects and young subjects of Leiden origin (6.3% and
7.6%, respectively; data not shown). Separate analysis of
men and women did not reveal significant differences.
The 10-year mortality risk of elderly subjects carrying
both the ACE D/D and PAI-1 4G/4G genotype was 0.8
(95% CI 0.6 to 1.2) from any cause and 0.9 (95% CI 0.5 to
1.5) from cardiovascular disease as compared with that of a
reference group of double heterozygous subjects and sub-
jects homozygous for the ACE I-allele and/or the PAI-1
5G-allele. It was not possible to test for an association with
death from ischemic heart disease because the number of
subjects was too small.
DISCUSSION
ACE I/D polymorphism. No evidence was obtained for
increased (cardiovascular) mortality among carriers of the
ACE D/D genotype in the cross-sectional comparison of
young and elderly subjects or in the 10-year follow-up study
among elderly subjects. Other cross-sectional studies also
showed similar ACE D/D frequencies in elderly subjects of
about the same age as those in our study (11,37). A
decreased prevalence of the ACE D/D genotype in hyper-
tensive subjects $60 years old was reported, suggesting that
the ACE D/D genotype may confer an increased mortality
in this high risk subgroup (38). Increased mortality in the
population at large has, however, not been observed in our
study.
Although the neutral ACE I/D polymorphism explains
14% to 25% of the variance in ACE level (1,2), there is
much debate about the significance of the relation between
the ACE polymorphism and cardiovascular disease. The
conflicting results of the studies performed thus far can be
attributed to differences in clinical phenotype (such as
myocardial infarction and coronary artery disease), differ-
ences in the age of the subjects, representativeness of control
subjects and differences in environmental and genetic back-
ground. Moreover, a meta-analysis of the association be-
tween the ACE I/D polymorphism and myocardial infarc-
Figure 2. Kaplan-Meier estimate of 10-year cumulative survival
according to PAI-1 genotype for subjects $85 years old.
Table 4. Ten-Year All-Cause and Cardiovascular Disease Mortality Risks According to Plasminogen Activator Inhibitor-1 Genotype
in Subjects $85 Years Old
PAI-1
Genotype n
All-Cause
Cardiovascular
Disease
Ischemic Heart
Disease
Cerebrovascular
Disease
RR* 95% CI RR 95% CI RR 95% CI RR 95% CI
All subjects 644 n 5 575 n 5 242 n 5 61 n 5 78
5G/5G 124 1 1 1 1
4G/5G 340 0.8 (0.7–1.0) 0.9 (0.6–1.2) 0.9 (0.5–2.0) 0.9 (0.5–1.6)
4G/4G 180 0.9 (0.7–1.1) 0.9 (0.6–1.3) 1.6 (0.8–3.3) 0.7 (0.4–1.4)
Men only 181 n 5 159 n 5 61 n 5 19 n 5 19
5G/5G 32 1 1 1 1
4G/5G 95 1.9 (0.8–1.8) 1.3 (0.6–2.6) 3.3 (0.4–27) 2.5 (0.6–11)
4G/4G 54 1.2 (0.8–2.0) 1.6 (0.7–3.4) 8.2 (1.0–64) 1.9 (0.4–10)
Women only 463 n 5 416 n 5 181 n 5 42 n 5 59
5G/5G 92 1 1 1 1
4G/5G 245 0.7 (0.6–0.9) 0.8 (0.5–1.1) 0.7 (0.3–1.5) 0.7 (0.4–1.3)
4G/4G 126 0.8 (0.6–1.0) 0.7 (0.5–1.1) 0.9 (0.4–2.2) 0.6 (0.3–1.2)
*Relative risk (RR) indicates the mortality risk as estimated by a Cox proportional hazard model adjusted for age at baseline.
CI 5 confidence interval; PAI-1 5 plasminogen activator inhibitor-1.
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tion suggested a publication bias toward positive results for
the smaller studies (36).
A number of relatively large studies reported an associa-
tion of the ACE D/D genotype with a history of myocardial
infarction (4–7). In some studies the association was found
to be stronger (4,39) or present only (9,15) in subgroups
otherwise at a low risk using different criteria. Furthermore,
the prevalence of the ACE D/D genotype was increased
among patients who had a fatal myocardial infarction (40).
However, most larger studies, eight in total including the
only prospective study, found no evidence for an association
with myocardial infarction (8–14) or ischemic heart disease
(15). Also, in most studies, no association was observed in
low risk subjects (5,8,10,12,13). Our observation—that the
ACE D/D genotype was not associated with mortality or
fatal cardiovascular disease in old age—indicates that the
overall effect of the ACE polymorphisms on fatal disease is
probably limited.
Scha¨chter et al. (16) reported an increased prevalence of
the ACE D/D genotype in French centenarians as com-
pared with subjects 20 to 70 years old. They suggested that
the ACE D/D genotype might be deleterious in middle age,
but beneficial to survival in very old age. Recently, the same
group developed a mathematic model predicting trajectories
of genotype frequencies in aging cohorts as a consequence of
differential population mortality rates for the genotypes
(41). This model indicated that any genotype with an effect
on survival before 95 years of any exhibits an opposite effect
after this age. The increased frequency of the ACE D/D
genotype in French centenarians was thus explained by
assuming an increased mortality of ACE D/D carriers
before 95 years old. Neither in our cross-sectional analysis
nor in the prospective follow-up study among subjects
$85-years-old could we find support for this assumption. In
addition, no increased ACE D/D frequency was found in
187 Danish centenarians (42).
PAI-1 4G/5G polymorphism. We found that men $85
years old carrying the PAI-1 4G/4G genotype were at a
threefold increased risk of death due to ischemic heart
disease during a 10-year follow-up period. This was not
reflected in the risk of death from all cardiovascular causes
combined or increased mortality before the age of 85 years.
The indication that the PAI-1 polymorphism may contrib-
ute to the development of ischemic heart disease in old age
significantly extends the previous findings that the PAI-1
4G/4G genotype is a risk factor for premature myocardial
infarction, which has a much lower incidence (patients ,45
years old [18], mean age 58 years [24,26]). It should,
however, be noted that although our study is prospective
and thus not prone to bias, our findings are based on the
analysis of a small subset and therefore require confirmation
in more extensive studies.
In contrast to our studies and those mentioned earlier, as
well as a study showing a higher prevalence of the PAI-1
4G/4G genotype among subjects with a family history of
coronary heart disease (25), the PAI-1 polymorphism was
not associated with myocardial infarction in the Etude
Cas-Temoins sur l’Infarctus du Myocarde (ECTIM) study
(men 25 to 64 years old) (19) and the Physicians’ Health
Study (men 40 to 84 years old, mean follow-up eight years)
(23). The variable outcomes of these studies may have
resulted from chance, but may also point to population
differences with respect to the pathogenesis of myocardial
infarction or the prevalence of environmental factors mod-
ifying the effect of the PAI-1 polymorphism.
The current study could not provide an explanation for
the gender-specificity of the association with fatal ischemic
heart disease. One previous study also reported data on both
genders separately, and these showed that the PAI-1
4G/4G genotype was a risk factor for myocardial infarction
in men only (26). Hormonal differences with respect to
estrogen are not likely to play a role because the elderly
women were well beyond their menopause. Smoking has
been suggested to modify the effect of the polymorphism
(43). Different smoking habits between men and women
might have explained our observation, but the numbers were
too small to test for this possibility. Another explanation
could have been a different prevalence of diabetes in men
and women, because the effect of the PAI-1 4G/4G
genotype is known to be more pronounced in individuals
with features of insulin resistance (elevated levels of triglyc-
erides, insulin and glucose) (20,21). However, none of the
men who carried the apparently deleterious PAI-1 genotype
and died of ischemic heart disease had been diagnosed as
having diabetes. Overall, the (cardiovascular) mortality was
not increased in elderly subjects carrying the 4G/4G geno-
type with diabetes. In contrast, the mortality risk in these
patients was even significantly reduced. We do not have an
explanation for this finding.
Interaction. Recent studies showed that the PAI-1 4G/4G
as well as the ACE D/D genotype is associated with
increased PAI-1 levels (28,29). Although the possible del-
eterious effect on mortality of a decreased fibrinolytic
capacity might have been more readily observed in subjects
carrying both risk genotypes, none of our analyses indicated
an increased mortality in this subgroup.
Study limitations. Our study indicates that it is unlikely
that the putative ACE and PAI-1 risk genotypes have a
major influence on mortality in the population at large. On
the basis of the 95% CIs, the overall mortality risks can be
expected to be ,1.2-fold increased. The current study does
not, however, have sufficient power to exclude associations
between polymorphisms and specific causes of death, owing
to the relatively small numbers of subjects in these subsets.
In these subsets, nondifferential misclassification of causes
of death could be expected to have occurred because they
were not confirmed at necropsy, which leads to an under-
estimation of the risk estimates. We have previously re-
ported associations with single specific causes of death,
indicating that the registry data have significant power to
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discriminate between the various causes of death (30,31,44).
Furthermore, it has been shown in the United Kingdom
that underreporting of cerebrovascular and cardiovascular
mortality as an underlying cause of death occurs relatively
infrequently (45). In the case of .90% of the individuals
who died within four weeks of hospital admission because of
stroke or ischemic heart disease, the disease was mentioned
on the death certificate.
Conclusions. We conclude that the influence on disease
risk of moderately increased ACE and PAI-1 activities that
are associated with the ACE D/D and the PAI-1 4G/4G
genotype is not large enough to affect mortality in the
general population. Our data suggest, however, that the
PAI-1 4G/4G genotype may play a role in fatal ischemic
heart disease in elderly men. This observation requires
confirmation in larger prospective studies.
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